Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

RTTNews | 360 days ago
Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) and Daiichi Sankyo Europe GmbH or DSE, the European arm of Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (DSKYF.PK), announced Wednesday a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet.

DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

The legal action pending in the United States District Court for the Southern District of New York will be dismissed.

Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

read more
Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
RTTNews | 372 days ago
TSX Ends Modestly Lower

TSX Ends Modestly Lower

https://money.tmx.com/canadian-markets https://www.rttnews.com/3499633/bay-street-likely-to-open-slightly-higher.aspx?type=cn
RTTNews | 19h 53min ago
Swiss Market Ends On Firm Note

Swiss Market Ends On Firm Note

The Switzerland market closed on a firm note on Friday, in line with markets across Europe, as investors picked up stocks from across several sectors. The benchmark SMI closed up 101.06 points or 0.88% at 11,589.34, slightly off the day's high of 11,597.29.
RTTNews | 23h 45min ago
European Markets Close Higher

European Markets Close Higher

European stocks closed higher on Friday, as investors made some purchases at several counters as markets resumed trading after Christmas holidays. Activity was a bit subdued in most of the markets in the region amid a lack of triggers, and ahead of the New Year holidays coming up next week.
RTTNews | 1 day ago